Huang Ju, Wu Liu, Ren Xiaodan, Wu Xinhui, Chen Yong, Ran Guoping, Huang Anming, Huang Liangxin, Zhong Dan
College of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu.
Medicine (Baltimore). 2020 Aug 28;99(35):e21774. doi: 10.1097/MD.0000000000021774.
Assessing the effectiveness and safety of Traditional Chinese medicine for treating patients with corona virus disease 2019 (COVID-19) is the main purpose of this systematic review protocol.
The following electronic databases will be searched from inception to April 2020: Cochrane Central Register of Controlled Trials, PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, Traditional Chinese Medicine, Chinese Biomedical Literature Database, Wan-Fang Database, and Chinese Scientific Journal Database. All published randomized controlled trials in English or Chinese related to Traditional Chinese medicine for COVID-19 will be included. Primary outcomes are time of disappearance of main symptoms and serum cytokine levels. Secondary outcomes is Accompanying symptoms disappear rate, negative COVID-19 results rate on 2 consecutive occasions CT image improvement, average hospitalization time, occurrence rate of common type to severe form, clinical cure rate, and mortality. Two reviewers will conduct the study selection, data extraction, and assessment independently. The assessment of risk of bias and data synthesis will be conducted with Review Manager Software V.5.2.
The results will provide a high-quality synthesis of current evidence for researchers in this subject area.
The conclusion of our study will provide evidence to judge whether traditional Chinese medicine is an effective intervention for COVID-19 patients.
CRD42020181006.
评估中医药治疗2019冠状病毒病(COVID-19)患者的有效性和安全性是本系统评价方案的主要目的。
从建库至2020年4月检索以下电子数据库:Cochrane对照试验中心注册库、PubMed、科学引文索引、EMBASE、中国知网、中国生物医学文献数据库、万方数据库和维普资讯网。纳入所有已发表的关于中医药治疗COVID-19的英文或中文随机对照试验。主要结局为主要症状消失时间和血清细胞因子水平。次要结局为伴随症状消失率、连续2次新型冠状病毒核酸检测阴性率、CT影像改善情况、平均住院时间、普通型转为重型发生率、临床治愈率和死亡率。两名评价员将独立进行研究筛选、数据提取和评估。采用Review Manager软件V.5.2进行偏倚风险评估和数据合成。
结果将为本学科领域的研究人员提供高质量的当前证据综合。
我们研究的结论将为判断中医药是否为COVID-19患者的有效干预措施提供证据。
CRD42020181006。